CORRELATION BETWEEN P53 EXPRESSION AND CLINICOPATHOLOGICAL FEATURES OF GLIOBLASTOMA – A STUDY AT CHO RAY HOSPITAL

Quang Phạm Duy, Duy Nguyễn Đức, Thông Phạm Quang, Phát Hồ Thị Hồng, Hạnh Ngô Thị Tuyết, Thịnh Hoàng Văn, Huy Lê Minh

Main Article Content

Abstract

Objectives: To evaluate the association between p53 expression and clinical–histopathological features in glioblastoma. Materials and Methods: A descriptive case series study was conducted on 100 glioblastoma cases at Cho Ray Hospital. p53 expression was assessed by immunohistochemistry and categorized as normal or abnormal. Clinical data, imaging findings, and histopathological features were retrospectively collected and analyzed for their association with p53 expression using appropriate statistical tests. Results: Abnormal p53 expression was observed in 47% of cases. This expression was significantly associated with younger patient age (p < 0.001), sampling method (p = 0.022), histological subtype (p = 0.004), and the presence of multinucleated giant cells (p = 0.001). Multivariate logistic regression analysis identified three independent factors associated with abnormal p53 expression: age ≥ 50 years was associated with a lower risk of abnormal p53 expression (OR = 0.33; p = 0.019), a history of prior brain tumors also decreased the risk (OR = 0.14; p = 0.027), whereas the presence of multinucleated giant cells significantly increased the risk (OR = 4.35; p = 0.002). Conclusion: Abnormal p53 expression is strongly associated with certain histopathological features, particularly the presence of multinucleated giant cells, and tends to occur in younger patients without a prior history of brain tumors. These factors may contribute to risk stratification and guide monitoring and treatment strategies in glioblastoma patients. 

Article Details

References

1. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-oncology. 2021;23(8):1231-1251.
2. Sỹ Lánh N, Phúc Cương N, Thúy Hương N. Nghiên cứu phân loại mô bệnh học và một số dấu ấn Hóa mô miễn dịch của U thần kinh đệm lan tỏa của não theo phân loại của Tổ chức Y tế thế giới năm 2007. Tạp chí Y học Việt Nam. 2022;513(1).
3. Chaurasia A, Park S-H, Seo J-W, Park C-K. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival. J Korean Med Sci. 2016;31(8):1208-1214.
4. Silwal-Pandit L, Vollan HK, Chin SF, et al. TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014;20(13):3569-3580.
5. Jakovlevs A, Vanags A, Balodis D, Gardovskis J, Strumfa I. Heterogeneity of Ki-67 and p53 Expression in Glioblastoma. Acta Chirurgica Latviensis. 2014;14(1):11-14.
6. Shiraishi S, Tada K, Nakamura H, et al. Influence of p53 mutations on prognosis of patients with glioblastoma. Cancer. 2002;95(2):249-257.
7. Barresi V, Simbolo M, Mafficini A, et al. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation. Acta Neuropathologica Communications. 2021;9(1): 200.
8. Zhang Y, Dube C, Gibert M, Jr., et al. The p53 Pathway in Glioblastoma. Cancers. 2018;10(9).